MedPage Today) -- A novel combination for relapsed/refractory multiple myeloma produced responses in about 80% of a heavily treated population, albeit with a high incidence of hematologic toxicity and infections. The 94-patient cohort had an...
Copyright © 2023 ampere.org. All Rights Reserved